Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QVA149 versus glycopyrronium and tiotropium for prevention of COPD exacerbations
NL-OMON34930Phase 3Active, not recruiting
- Sponsor
- Novartis
- Start
- Jun 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in chronic obstructive pulmonary disease (COPD) comparing QVA149, NVA237 and Open-label tiotropium (3 arms). Primary endpoints: Rate of moderate to severe COPD exacerbations and Number of COPD exacerbations in 1.5 year. Started Jun 2010; status: active, not recruiting.
02
Drugs
indacaterol + glycopyrroniumglycopyrroniumtiotropium
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NL-OMON34930.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON34930.